A groundbreaking report from GlobalData predicts massive growth in the Alzheimer's treatment market over the next decade. The market is expected to surge from $2.4 billion to $19.3 billion, primarily driven by new disease-modifying therapies. Drugs like Leqembi and Kisunla are set to become top-selling treatments, despite challenges in administration and cost. The research highlights both exciting opportunities and significant barriers in Alzheimer's disease management.
"These new DMTs are significantly more expensive than the current highly genericised symptomatic treatments" - Philippa Salter, GlobalData by IANS
New expensive but disease-modifying treatments are expected to foster Alzheimer's disease market growth globally, according to a report.
Key Points
1. New disease-modifying therapies driving
exponential market expansion
2. Eight major markets show significant Alzheimer's
treatment potential
3. Expensive therapies expected to dominate global
market by 2033
4. Oral treatment options emerging to improve clinical integration
The report by GlobalData, a data and analytics
company, showed that the growth will particularly be visible in eight major
markets -- US, France, Germany, Italy, Spain, UK, Japan, and China.
The report forecasted that the Alzheimer's disease
market in these countries to grow from $2.4 billion in 2023 to $19.3 billion by
2033 at a compound annual growth rate (CAGR) of 23.4 per cent.
This will be primarily driven by the entry of
expensive disease-modifying therapies (DMTs) into the market, which will likely
result in increased treatment rates as more options become available. An ageing
global population leading to an increase in prevalent cases, and the launch of
novel symptomatic therapies for the treatment of agitation and psychosis
associated with Alzheimer's disease will also contribute to the growth.
By 2033, DMTs are expected to dominate the global
Alzheimer's disease market, contributing 73.5 per cent of the market, with
drugs targeting amyloid beta making up the majority of this, the report said.
Philippa Salter, Managing Neurology Analyst at
GlobalData, said that Eisai/Biogen's Leqembi (lecanemab) and Eli Lilly's
Kisunla (donanemab) will become the top-selling drugs for Alzheimer's, and
"will generate global sales of approximately $3.6 billion and $3.8
billion, respectively, by 2033".
The report also noted barriers for these DMTs, which
will limit their integration into clinical practice. Frequent IV administration
and access to positron emission tomography (PET) and magnetic resonance imaging
(MRI) scans are key economic and operational limiting factors for access to
these drugs.
"In addition to logistical factors, these new DMTs
are significantly more expensive than the current highly genericised
symptomatic treatments used in the management of AD, providing a further access
challenge in the form of reimbursement/payer restrictions," Salter said
To counter these, drugmakers are probing alternative
routes of administration. Several oral late-stage products in the pipeline can
enable easier integration into clinical practice.
These include Anavex Life Sciences' ANAVEX2-73
(blarcamesine), TauRx Therapeutics' LMTX (hydromethylthionine mesylate), and
Novo Nordisk's NN-6535 (semaglutide).
The new DMTs are only considered moderately effective,
so significant opportunity remains for more effective DMTs that do not just
slow progression but also stop the disease, with prevention being the end goal.
Beyond DMTS, drugs that can effectively improve
cognition in the late stages of the disease, as well as more effective options
for secondary symptoms such as agitation and psychosis, also provide
opportunities for developers.
No comments:
Post a Comment